Evidence rating insufficient. 15 sources indexed (2007–2026), with 4 interaction records on file.
Dosing
Dosing & protocol.
Common range
Not listed
Recommended form
Not listed
Dosing protocol
Maintain · Therapeutic context only (treatment-resistant depression); not a routine supplement
Listed for context; chronic recreational use causes ketamine cystitis. Therapeutic use is supervised IV or intranasal.
No cycling requiredTolerance can build
Forms
Forms & what to buy.
Ranked by evidence and value.
IV Ketamine Recommended
Rank 1: complete medical delivery with rapid onset. Limited direct form-comparison evidence; ranking is based on review or mechanistic data (PMID: 33128208). Administered only in clinical settings.
Rank 3: compounded lower-bioavailability route. Variable absorption and active metabolite exposure.
PremiumMedical guidance only
Cost
What it actually costs.
Real-world pricing across three quality tiers. Assumes Controlled medical-only substance.
BudgetBest value
$0.00 /mo
$0.00 per dose
Mid
$0.00 /mo
$0.00 per dose
Premium
$0.00 /mo
$0.00 per dose
No effective supplement dose exists. Cost is intentionally not modeled for this controlled medical-only substance. Updated 2026-05-28.
From food
The same dose, as food.
How much you'd eat to match a supplemental dose.
No nutritional supplemental dose
Not applicable as a whole-food equivalent.
Ketamine is a prescription anesthetic and dissociative drug, not a nutrient or food-derived supplement.
Lab work
Markers to track.
What to test, the optimal window inside the conventional range, and how long a response takes.
Urinary Norketamine Norketamine
Ketamine (including therapeutic IV and intranasal esketamine) is rapidly metabolized to norketamine; detection in urine for 2 to 5 days.14,15
Optimal
0–0 ng/mL
Conventional
0–50 ng/mL
Responds in
Detection window 2 to 5 days; therapeutic effect on depression scored by MADRS/PHQ-9 within hours to days.
0optimal50
Therapeutic ketamine for treatment-resistant depression is tracked by clinical scales, blood pressure, and urinary symptoms (chronic recreational use causes ketamine cystitis).
Blood Pressure
Genetics
Who responds differently.
CYP2B6reduced-function alleles~20% of population
Ketamine pharmacogenetic work has evaluated CYP2B6 variation in relation to ketamine-induced emergence phenomena (PMID 28252572).
Recommendation: If ketamine is used medically, genotype should only be interpreted by the treating clinician alongside dose, route, and psychiatric history.
Safety
Full safety detail.
Side effects
Dissociation and impaired judgment
Nausea and vomiting
Hypertension and tachycardia
Falls or trauma
Tolerance and psychological dependence
Ulcerative cystitis and lower urinary tract injury
Abdominal pain and possible liver abnormalities with chronic heavy use
Combining ketamine with alcohol produces additive central nervous system and respiratory depression, raising the risk of profound sedation, airway compromise, vomiting with aspiration, and loss of consciousness.
Recommendation: Do not combine. If both have been taken together and breathing is slow or shallow, consciousness is impaired, or vomiting occurs, seek emergency medical care immediately.
Supplemental GABA used as a calming or sleep aid may add to ketamine's sedative and dissociative load, deepening drowsiness and impairing coordination and alertness.
Recommendation: Do not combine GABA supplements with ketamine. If ketamine is being used and GABA has also been taken, do not drive or operate machinery and seek medical advice.
Valerian root has sedative-hypnotic activity that can add to ketamine's central depressant and dissociative effects, increasing drowsiness, dizziness, and impaired reaction time.
Recommendation: Do not combine valerian root with ketamine. If both are in use, avoid driving and other tasks requiring alertness and seek medical advice.
Sukhdeo R, Tamura JK, Dri CE et al.. Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2026
Rathore BS, Singh S, Gupta M et al.. Safety and efficacy of ketamine for the treatment of patients with alcohol use disorder: a systematic review. The American journal of drug and alcohol abuse. 2025
Umbacia MA, Calsina-Berna A, Hernández-Rico AN et al.. Oral Ketamine as an Analgesic Therapy: Systematic Review of Randomised Clinical Trials. Journal of pain & palliative care pharmacotherapy. 2025
Yan M, Sun T, Liu J et al.. The efficacy and safety of ketamine in the treatment of super-refractory status epilepticus: a systematic review. Journal of neurology. 2024
Liu Y, Yang J, Liu Y. Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety. Journal of psychiatric research. 2024
Petrucci ABC, Fernandes JVA, Reis IA et al.. Ketamine versus electroconvulsive therapy for major depressive episode: An updated systematic review and non-inferiority meta-analysis. Psychiatry research. 2024
Kwaśny A, Kwaśna J, Wilkowska A et al.. Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2024
Smith-Apeldoorn SY, Veraart JK, Spijker J et al.. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. The lancet. Psychiatry. 2022
Rhee TG, Shim SR, Forester BP et al.. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA psychiatry. 2022
Memon RI, Naveed S, Faquih AE et al.. Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review. The Psychiatric quarterly. 2020
Orhurhu V, Orhurhu MS, Bhatia A et al.. Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesia and analgesia. 2019
Scoping review found well-established abuse liability for racemic ketamine, with limited controlled-setting clinical data showing less misuse than seen in recreational contexts.
Case series of daily ketamine users documented severe lower urinary tract symptoms and inflammatory bladder injury consistent with ketamine-associated cystitis.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Ketamine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.